Risk of termination of joint research agreements with universities and related cost burdens
First written in FY2016. 1 of 3 entries say "Restated". Latest entry: FY2018.
OncoTherapy Science moved to the "Worse" side of this theme in 2018, 7 years before the typical company in this theme (2025).
The whole theme swung hardest in 2020: 2 of 6 companies on the "Worse" side.
1 other company's latest entry also says "Worsened".
- FY2018WorsenedAnnual report
「University of Chicago Research into new cancer treatment targets (Note) The above research is scheduled to end at the end of June 2018.」
The joint research with the University of Chicago is now specifically scheduled to end at the end of June 2018, bringing the risk of termination of the joint research agreement closer to materialization. Joint research expenses also fell to ¥119 million from ¥326 million in the previous period. - FY2017RestatedAnnual report
「Joint research expenses were ¥228 million in the fiscal year ended March 2013, ¥209 million in the fiscal year ended March 2014, ¥209 million in the fiscal year ended March 2015, ¥314 million in the fiscal year ended March 2016, and ¥326 million in the fiscal year ended March 2017.」
The company continues to disclose its policy of continuing joint research with universities and its associated joint research cost burden. - FY2016First statedAnnual report
「If renewal of the agreement becomes difficult, or if the agreement ends due to termination or any other reason, this could adversely affect the company's business.」
The group considers joint research with the University of Chicago and other institutions to be a foundation of its business. Joint research expenses for the current fiscal year were ¥314.666 million.